These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 22298660)

  • 1. Capecitabine non-adherence: exploration of magnitude, nature and contributing factors.
    Bhattacharya D; Easthall C; Willoughby KA; Small M; Watson S
    J Oncol Pharm Pract; 2012 Sep; 18(3):333-42. PubMed ID: 22298660
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adherence to capecitabine treatment and contributing factors among cancer patients in Malaysia.
    Zahrina AK; Norsa'adah B; Hassan NB; Norazwany Y; Norhayati I; Roslan MH; Wan Nazuha WR
    Asian Pac J Cancer Prev; 2014; 15(21):9225-32. PubMed ID: 25422205
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adherence and persistence with oral adjuvant chemotherapy in older women with early-stage breast cancer in CALGB 49907: adherence companion study 60104.
    Partridge AH; Archer L; Kornblith AB; Gralow J; Grenier D; Perez E; Wolff AC; Wang X; Kastrissios H; Berry D; Hudis C; Winer E; Muss H
    J Clin Oncol; 2010 May; 28(14):2418-22. PubMed ID: 20368559
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Study on adherence to capecitabine among patients with colorectal cancer and metastatic breast cancer.
    Figueiredo Junior AG; Forones NM
    Arq Gastroenterol; 2014; 51(3):186-91. PubMed ID: 25296077
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical features of oral chemotherapy: results of a longitudinal prospective study of breast and colorectal cancer patients receiving capecitabine in the UK.
    Brearley SG; Craven O; Saunders M; Swindell R; Molassiotis A
    Eur J Cancer Care (Engl); 2010 Jul; 19(4):425-33. PubMed ID: 19708942
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A randomised cross-over trial comparing patient preference for oral capecitabine and 5-fluorouracil/leucovorin regimens in patients with advanced colorectal cancer.
    Twelves C; Gollins S; Grieve R; Samuel L
    Ann Oncol; 2006 Feb; 17(2):239-45. PubMed ID: 16344278
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enhancing adherence to capecitabine chemotherapy by means of multidisciplinary pharmaceutical care.
    Simons S; Ringsdorf S; Braun M; Mey UJ; Schwindt PF; Ko YD; Schmidt-Wolf I; Kuhn W; Jaehde U
    Support Care Cancer; 2011 Jul; 19(7):1009-18. PubMed ID: 20552377
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oral capecitabine (Xeloda) in cancer treatment.
    Doyle DP; Engelking C
    Nurse Pract; 2007 Feb; 32(2):18-21. PubMed ID: 17264789
    [No Abstract]   [Full Text] [Related]  

  • 9. On prejudice and facts and choices.
    Köhne CH; Folprecht G
    Ann Oncol; 2006 Feb; 17(2):185-7. PubMed ID: 16428244
    [No Abstract]   [Full Text] [Related]  

  • 10. Safety profile and activity of lower capecitabine dose in patients with metastatic breast cancer.
    Rossi D; Alessandroni P; Catalano V; Giordani P; Fedeli SL; Fedeli A; Baldelli AM; Casadei V; Ceccolini M; Catalano G
    Clin Breast Cancer; 2007 Dec; 7(11):857-60. PubMed ID: 18269775
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cardiotoxicity of fluoropyrimidines in different schedules of administration: a prospective study.
    Kosmas C; Kallistratos MS; Kopterides P; Syrios J; Skopelitis H; Mylonakis N; Karabelis A; Tsavaris N
    J Cancer Res Clin Oncol; 2008 Jan; 134(1):75-82. PubMed ID: 17636329
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Over compliance with capecitabine oral chemotherapy.
    Allen J; Williamson S
    Int J Clin Pharm; 2014 Apr; 36(2):271-3. PubMed ID: 24532364
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of capecitabine monotherapy as the first-line treatment of metastatic HER2-negative breast cancer.
    Babacan T; Efe O; Hasirci AS; Demirci F; Buyukhatipoglu H; Balakan O; Sarici F; Kertmen N; Esin E; Akin S; Ates O; Aksoy S; Sever AR; Altundag K
    Tumori; 2015; 101(4):418-23. PubMed ID: 25953439
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Implementation of capecitabine (Xeloda) into a cancer centre: UK experience.
    Faithfull S; Deery P
    Eur J Oncol Nurs; 2004; 8 Suppl 1():S54-62. PubMed ID: 15341882
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Oral capecitabine therapy: experience and developments at the Milano Cancer Institute].
    Longo F; Mansueto G
    Tumori; 2004; 90(1):suppl 17-27. PubMed ID: 15143996
    [No Abstract]   [Full Text] [Related]  

  • 16. [Capecitabine in colorectal carcinoma: news from ASCO 2008]].
    Longo F; Mansueto G
    Tumori; 2008; 94(4):suppl 15-23. PubMed ID: 18822712
    [No Abstract]   [Full Text] [Related]  

  • 17. Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study.
    Van Cutsem E; Twelves C; Cassidy J; Allman D; Bajetta E; Boyer M; Bugat R; Findlay M; Frings S; Jahn M; McKendrick J; Osterwalder B; Perez-Manga G; Rosso R; Rougier P; Schmiegel WH; Seitz JF; Thompson P; Vieitez JM; Weitzel C; Harper P;
    J Clin Oncol; 2001 Nov; 19(21):4097-106. PubMed ID: 11689577
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Capecitabine versus continuous-infusion 5-fluorouracil for colorectal cancer: a retrospective efficacy and safety comparison.
    Saif MW
    Clin Colorectal Cancer; 2005 Jul; 5(2):89-100. PubMed ID: 16098249
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New options for outpatient chemotherapy--the role of oral fluoropyrimidines.
    Cunningham D; Coleman R
    Cancer Treat Rev; 2001 Aug; 27(4):211-20. PubMed ID: 11545541
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Capecitabine: an overview of the side effects and their management.
    Saif MW; Katirtzoglou NA; Syrigos KN
    Anticancer Drugs; 2008 Jun; 19(5):447-64. PubMed ID: 18418212
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.